Genous™ endothelial progenitor cell-capturing stent system: A novel stent technology

Expert Review of Medical Devices

Volumn 6, Issue 4, 2009, Pages 365-375

  Klomp, Margo ^a   Beijk, Marcel A M ^a   de Winter, Robbert J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Endothelial progenitor cell; Percutaneous coronary intervention; Restenosis; Stent; Stent thrombosis

Indexed keywords

ATORVASTATIN; CD133 ANTIGEN; CD34 ANTIBODY; CHROMIUM; COBALT; PACLITAXEL; RAPAMYCIN; STAINLESS STEEL;

ANGIOCARDIOGRAPHY; ANGIOGENESIS; BALLOON CATHETER; BARE METAL STENT; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; ENDOTHELIAL PROGENITOR CELL CAPTURING STENT; ENDOTHELIUM CELL; EQUIPMENT DESIGN; EXTRACELLULAR MATRIX; FEASIBILITY STUDY; FLOW CYTOMETRY; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; REVIEW; SAFETY; SCANNING ELECTRON MICROSCOPY; ST SEGMENT ELEVATION; STEM CELL; BLOOD VESSEL PROSTHESIS; CELL SEPARATION; CYTOLOGY; EQUIPMENT; HEMATOPOIETIC STEM CELL; IMMOBILIZED CELL; INSTRUMENTATION; TISSUE REGENERATION;

BLOOD VESSEL PROSTHESIS; CELL SEPARATION; CELLS, IMMOBILIZED; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; GUIDED TISSUE REGENERATION; HEMATOPOIETIC STEM CELLS;

EID: 69949115470     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.09.16     Document Type: Review

References (71)

1. Colombo A, Drzewiecki J, Banning A et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108(7), 788-794 (2003).
2. Fajadet J, Wijns W, Laarman GJ et al. Randomized, double-blind, multicenter study of the ENDEAVOR zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial. Minerva Cardioangiol. 55(1), 1-18 (2007).
3. Grube E, Silber S, Hauptmann KE et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107(1), 38-42 (2003).
4. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346(23), 1773-1780 (2002).
5. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349(14), 1315-1323 (2003).
6. Stone GW, Midei M, Newman W et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299(16), 1903-1913 (2008).
7. Hofma SH, van der Giessen WJ, van Dalen BM et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur. Heart J. 27(2), 166-170 (2006).
8. Togni M, Windecker S, Cocchia R et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol. 46(2), 231-236 (2005).
9. Finn AV, Nakazawa G, Joner M et al. Vascular responses to drug eluting stents. importance of delayed healing. Arterioscler. Thromb. Vasc. Biol. 27(7), 1500-1510 (2007).
10. Finn AV, Joner M, Nakazawa G et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115(18), 2435-2441 (2007).
11. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293(17), 2126-2130 (2005).
12. Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48(1), 193-202 (2006).
13. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J. Am. Coll. Cardiol. 45(12), 2088-2092 (2005).
14. Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356(10), 998-1008 (2007).
15. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302), 964-967 (1997).
16. Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85(3), 221-228 (1999).
17. Hill JM, Zalos G, Halcox JP et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348(7), 593-600 (2003).
18. Kawamoto A, Asahara T. Role of progenitor endothelial cells in cardiovascular disease and upcoming therapies. Catheter. Cardiovasc. Interv. 70(4), 477-484 (2007).
19. Schmidt-Lucke C, Rossig L, Fichtlscherer S et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111(22), 2981-2987 (2005).
20. Young PP, Vaughan DE, Hatzopoulos AK. Biologic properties of endothelial progenitor cells and their potential for cell therapy. Prog. Cardiovasc. Dis. 49(6), 421-429 (2007).
21. Kong D, Melo LG, Mangi AA et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 109(14), 1769-1775 (2004).
22. Werner N, Junk S, Laufs U et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ. Res. 93(2), E17-E24 (2003).
23. Kutryk MJ, Kuliszewski MA. In vivo endothelial progenitor cell seeding for the accelerated endothelialization of endovascular devices. Am. J. Cardiol. 92(6), 94L (2003).
24. Aoki J, Serruys PW, van Beusekom H et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J. Am. Coll. Cardiol. 45(10), 1574-1579 (2005).
25. Duckers HJ, Silber S, de Winter RJ et al. Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent. EuroIntervention 3, 67-75 (2007).
26. Duckers HJ, Soullie T, den Heijer P et al. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the HEALING II trial using an endothelial progenitor cell capturing stent (Genous R stent)™. EuroIntervention 3, 350-358 (2007).
27. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 105(1), 71-77 (2000).
28. + cells identifies a population of functional endothelial precursors. Blood 95(3), 952-958 (2000).
29. Sieveking DP, Buckle A, Celermajer DS, Ng MK. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J. Am. Coll. Cardiol. 51(6), 660-668 (2008).
30. Vasa M, Fichtlscherer S, Aicher A et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89(1), E1-E7 (2001).
31. Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C. Impaired progenitor cell activity in age-related endothelial dysfunction. J. Am. Coll. Cardiol. 45(9), 1441-1448 (2005).
32. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 108(4), 457-463 (2003).
33. Scheubel RJ, Zorn H, Silber RE et al. Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J. Am. Coll. Cardiol. 42(12), 2073-2080 (2003).
34. Hoetzer GL, MacEneaney OJ, Irmiger HM et al. Gender differences in circulating endothelial progenitor cell colony-forming capacity and migratory activity in middle-aged adults. Am. J. Cardiol. 99(1), 46-48 (2007).
35. Ii M, Takenaka H, Asai J et al. Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. Circ. Res. 98(5), 697-704 (2006).
36. Tepper OM, Galiano RD, Capla JM et al. Human endothelial progenitor cells from Type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106(22), 2781-2786 (2002).
37. Chen JZ, Zhang FR, Tao QM, Wang XX, Zhu JH, Zhu JH. Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. Clin. Sci. (Lond.) 107(3), 273-280 (2004).
38. Michaud SE, Dussault S, Haddad P, Groleau J, Rivard A. Circulating endothelial progenitor cells from healthy smokers exhibit impaired functional activities. Atherosclerosis 187(2), 423-432 (2006).
39. George J, Herz I, Goldstein E et al. Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler. Thromb. Vasc. Biol. 23(12), E57-E60 (2003).
40. Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353(10), 999-1007 (2005).
41. Heeschen C, Lehmann R, Honold J et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 109(13), 1615-1622 (2004).
42. Massa M, Rosti V, Ferrario M et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 105(1), 199-206 (2005).
43. George J, Goldstein E, Abashidze S et al. Circulating endothelial progenitor cells in patients with unstable angina: association with systemic inflammation. Eur. Heart J. 25(12), 1003-1008 (2004).
44. Shintani S, Murohara T, Ikeda H et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103(23), 2776-2779 (2001).
45. Wojakowski W, Kucia M, Kazmierski M, Ratajczak MZ, Tendera M. Circulating progenitor cells in stable coronary heart disease and acute coronary syndromes: relevant reparatory mechanism? Heart 94(1), 27-33 (2008).
46. Laufs U, Werner N, Link A et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109(2), 220-226 (2004).
47. Strehlow K, Werner N, Berweiler J et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 107(24), 3059-3065 (2003).
48. Dimmeler S, Aicher A, Vasa M et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 108(3), 391-397 (2001).
49. Landmesser U, Engberding N, Bahlmann FH et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110(14), 1933-1939 (2004).
50. Vasa M, Fichtlscherer S, Adler K et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103(24), 2885-2890 (2001).
51. Walter DH, Rittig K, Bahlmann FH et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105(25), 3017-3024 (2002).
52. Heeschen C, Aicher A, Lehmann R et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102(4), 1340-1346 (2003).
53. Banerjee S, Brilakis E, Zhang S et al. Endothelial progenitor cell mobilization after percutaneous coronary intervention. Atherosclerosis 189(1), 70-75 (2006).
54. Bonello L, Basire A, Sabatier F, Paganelli F, Dignat-George F. Endothelial injury induced by coronary angioplasty triggers mobilization of endothelial progenitor cells in patients with stable coronary artery disease. J. Thromb. Haemost. 4(5), 979-981 (2006).
55. Garg R, Tellez A, Alviar C, Granada J, Kleiman NS, Lev EI. The effect of percutaneous coronary intervention on inflammatory response and endothelial progenitor cell recruitment. Catheter. Cardiovasc. Interv. 72(2), 205-209 (2008).
56. Kutryk MJ, Kuliszewski MA. In vivo endothelial progenitor seeding of stented arterial segments and vascular grafts. Circulation 108(Suppl.), IV-573 (2003).
57. Kutryk MJ, Kuliszewski MA. The future beyond drug eluting stents: endothelial cell capture. Int. Symp. Endovasc. Ther. Course Syllabus, 125-129 (2004).
58. Duckers HJ, Soullie T, den Heijer P et al. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent)™. EuroIntervention 3(3), 350-358 (2007).
59. Miglionico M, Patti G, D'Ambrosio A, Di Sciascio G. Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: a prospective single-center registry in high-risk patients. Catheter. Cardiovasc. Interv. 71(5), 600-604 (2008).
60. Co M, Tay E, Lee CH et al. Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: intermediate- to long-term clinical follow-up. Am. Heart J. 155(1), 128-132 (2008).
61. Cervinka P, Bystron M, Spacek R, Kvasnak M, Jakabcin J. Randomized comparison of Genous stent versus Chromium-Cobalt stent for treatment of ST elevation myocardial infarction. 6-month clinical angiographic and IVUS follow-up. Genius-STEMI trial. Presented at: American College of Cardiology I2 Summit 2009. Orlando, FL, USA, 28 March 2009.
62. Kaul U, Bhatia V, Ghose T, Gupta R, Kachru R, Singh G. Angiographic follow-up of genous bioengineered stent in acute myocardial infarction (GENAMI) - a pilot study. Indian Heart J. 60(6), 532-535 (2008).
63. Tan HC. The use of endothelial progenitor cell capture stent in patients with ST-segment elevation myocardial infarction: 1-year clinical and angiographic outcomes. Presented at: China Interventional Therapeutics 2009. Beijing, China, 19 March 2009.
64. de Winter RJ. The OrbusNeich GENOUS EPC-Capture stent clinical trial program; e-HEALING, AMC registry, TRIAS. Presented at: TCT 2008: Transcatheter Cardiovascular Therapeutics 20th Annual Scientific Symposium. Washington, DC, USA, 12-17 October 2008.
65. Silber S. First results of the 1-year follow-up for the endothelial progenitor cells (EPC) capturing genous stent. Presented at: American Heart Association Scientific Sessions 2008. New Orleans, LA, USA, 8-12 November 2008.
66. Assmus B, Urbich C, Aicher A et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ. Res. 92(9), 1049-1055 (2003).
67. Bustos C, Hernandez-Presa MA, Ortego M et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll. Cardiol. 32(7), 2057-2064 (1998).
68. Llevadot J, Murasawa S, Kureishi Y et al. HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J. Clin. Invest. 108(3), 399-405 (2001).
69. Duckers HJ, Onuma Y, Benit E et al. Final results of the HEALING 2B trial to evaluate a bioengineered CD34 antibody coated stent (Genous Stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients. Presented at: American Heart Association Scientific Sessions 2008. New Orleans, LA, USA, 8-12 November 2008.
70. de Winter RJ. The Genous pro-healing stent: plan for the best, insure against the worst. Presented at: Joint Interventional Meeting 2009. Rome, Italy, 12-14 February 2009.
71. Klomp M, Beijk MA, Verouden C et al. One-year clinical outcome of a real world experience in patients treated with a Genous™ EPC capturing stent. Presented at: American Heart Association Scientific Sessions 2008. New Orleans, LA, USA, 8-12 November 2008.